Element Capital Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Element Capital Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-12,645	Closed	-$188K	–	958
2018 Q3	$188K	Sell	12,645 -16,747	-57%	-$263K	﹤0.01%	796
2018 Q2	$495K	Buy	29,392 +4,029	+16%	+$78.3K	0.01%	378
2018 Q1	$581K	Buy	+25,363	New	+$564K	0.01%	279

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Element Capital Management's CNCE Position: Q4 2018 in Review

Element Capital Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2018, closing a stake of 12,645 shares — an estimated $188K sold.

Element Capital Management first reported a position in CNCE in Q1 2018 and held it in 3 quarters. The position peaked at $581K in Q1 2018. 93 funds tracked by Wall St. Rank hold CNCE as of Q4 2018.

Element Capital Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Element Capital Management sold 12,645 Concert Pharmaceuticals, Inc. shares in Q4 2018, an estimated $188K.
Element Capital Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 3 quarters.
Element Capital Management's Concert Pharmaceuticals, Inc. position peaked at $581K in Q1 2018.
93 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.